Search Results - "Burcombe, R."

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.

Authors: Burcombe, R. J. Makris, A. Richman, P. I. et al.

Source: British Journal of Cancer. 1/17/2005, Vol. 92 Issue 1, p147-155. 9p.

Pre-treatment Haemoglobin Levels and the Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

Authors: Beresford, M.J. Burcombe, R. Ah-See, M.-L. et al.

Source: Clinical Oncology. Aug2006, Vol. 18 Issue 6, p453-458. 6p.

142P Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER+) early breast cancer (EBC): An observational single centre study.

Authors: Harper-Wynne, C. Burcombe, R.

Source: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS82-S82. 1p.

Massive Mediastinal Seminoma Post-orchidectomy Late relapse with Skip-metastases or New Primary?

Authors: Brown, R. S. D. Hayne, D. Burcombe, R. J. et al.

Source: Scandinavian Journal of Urology & Nephrology. Oct2001, Vol. 35 Issue 5, p422-424. 3p.

153 A review of concurrent chemoradiotherapy using cisplatin and oral vinorelbine in patients with non-small cell lung cancer (NCSLC) at the Kent Oncology Centre

Authors: Baldry, C. Burcombe, R. Taylor, H. et al.

Source: Lung Cancer (01695002). Jan2012 Supplement 1, Vol. 75, pS50-S50. 1p.

Chemotherapy review: Moving to a shared care model

Authors: Burcombe, R. Maynard, C.

Source: Lung Cancer (01695002). Jan2010 Supplement 1, Vol. 67, pS9-S9. 1p.

Hyperhomocysteinemia in women with advanced breast cancer.

Authors: GATT, A. MAKRIS, A. CLADD, H. et al.

Source: International Journal of Laboratory Hematology. Dec2007, Vol. 29 Issue 6, p421-425. 5p. 3 Graphs.

The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience.

Authors: Sim, V. Forner, S. Burcombe, R. et al.

Source: Clinical Oncology. Jul2019, Vol. 31 Issue 7, pe114-e114. 1p.

The Use of Oncotype DX in Adjuvant Chemotherapy Decision-making in Early Breast Cancer Patients with Intermediate Risk of Mortality at 10 Years.

Authors: Ramessur, A. Harper-Wyne, C. Burcombe, R. et al.

Source: Clinical Oncology. Jun2017, Vol. 29 Issue 6, pe103-e103. 1p.

183 Treating extensive stage small cell lung carcinoma in poor performance status patients – is a high 30 day mortality rate justifiable?

Authors: Bird, T. Shiarli, A. Burcombe, R. et al.

Source: Lung Cancer (01695002). Jan2014 Supplement, Vol. 83 Issue s1, pS68-S68. 1p.

180 A review of treatment of limited stage small cell lung carcinoma at the Kent Oncology Centre.

Authors: Sevitt, T. Shiarli, A. Burcombe, R. et al.

Source: Lung Cancer (01695002). Jan2014 Supplement, Vol. 83 Issue s1, pS66-S67. 0p.

145 Radical chemoradiation in non-small cell lung cancer – does the number of chemotherapy cycles matter?

Authors: Sambasivan, K. Baldry, C. Burcombe, R. et al.

Source: Lung Cancer (01695002). Jan2014 Supplement, Vol. 83 Issue s1, pS53-S53. 1p.

14 Audit of the management of epithelial growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients within the Kent Oncology Centre and its associated units

Authors: Biondo, A. Beesley, S. Burcombe, R. et al.

Source: Lung Cancer (01695002). Jan2012 Supplement 1, Vol. 75, pS5-S5. 1p.

19 A Kent and Medway Cancer Network (KMCN) audit of first-line treatment with cisplatin/pemetrexed (CisPem) in non squamous non-small cell lung cancer (NSCLC)

Authors: Letsa, I. Mikropoulos, C. Burcombe, R. et al.

Source: Lung Cancer (01695002). Jan2011 Supplement 1, Vol. 71, pS7-S7. 1p.

Small cell lung cancer (SCLC): Selecting patients for chemotherapy is more complex than just assessing performance status

Authors: Masson, S. Shah, R. Burcombe, R. et al.

Source: Lung Cancer (01695002). Jan2010 Supplement 1, Vol. 67, pS11-S11. 1p.

PO-0882: Single centre review of the survival benefit and toxicity of PCI in Small Cell Lung Cancer.

Authors: Forner, S. Vasiliadou, I. Little, J. et al.

Source: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS473-S474. 2p.

354 Poster - Enhanced axillary assessment using contrast enhanced ultrasound (CEUS) before neo-adjuvant systemic therapy (NACT) in breast cancer patients identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant.

Authors: Cox, K. Dineen, N. Weeks, J. et al.

Source: European Journal of Cancer. 2020 Supplement 1, Vol. 138, pS89-S89. 1p.

SABR implementation at a regional cancer centre: first-year outcomes and challenges at the Kent Oncology Centre.

Authors: Forner, S. Cominos, M. Brown, J. et al.

Source: Lung Cancer (01695002). Jan2019:Supplement 1, Vol. 127, pS75-S75. 1p.

223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience.

Authors: Forner, S Sim, V R Glendenning, J L et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.

Decision-making for Adjuvant Chemotherapy in the Absence of Genomic Testing for Breast Cancer Patients with ‘Intermediate’ Risk of Mortality at 10 Years.

Authors: Alrifai, D. Harper-Wynne, C. Jyothirmayi, R. et al.

Source: Clinical Oncology. May2016, Vol. 28 Issue 5, pe2-e2. 1p.